lung cancer
Conditions
Interventions
Observation group:NA
Sponsors
Affiliated Hospital of Guilin Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old; 2. Histopathological diagnosis of locally advanced NSCLC (AJCC 8th edition); 3. Judgment that it cannot be surgically resected (based on chest CT, PET-CT and mediastinoscopy evaluation); 4. Receiving >= 2 cycles of platinum-containing chemotherapy (cisplatin/carboplatin/nidaplatin + pemetrexed/paclitaxel/gemcitabine, etc.) combined with PD-1/PD-L1 inhibitors (tislelizumab, pembrolizumab, sintilimab, etc.); 5. The interval from diagnosis to the first chemotherapy =8 weeks apart) can be evaluated; 8. Survival status can be confirmed by hospital system or telephone follow-up.
Exclusion criteria
Exclusion criteria: 1. Driver gene positive: EGFR-sensitive mutation (Ex19del/L858R), ALK/ROS1/RET/MET fusion, etc.; 2. Previous neoadjuvant chemotherapy, immunotherapy or other systemic anti-cancer therapy; 3. Active autoimmune disease (requiring immunosuppressant therapy), interstitial lung disease (CTCAE=grade 2), etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median overall survival time;Disease Control Rate;Objective Response Rate;12-month survival rate;12-month progression-free survival;Adverse events; | — |
Countries
China
Contacts
Public ContactZhu Lin
Affiliated Hospital of Guilin Medical College
Outcome results
None listed